Literature DB >> 17400324

Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury.

Yi-Shin Huang1, Wei-Juin Su, Yi-Hsiang Huang, Chih-Yen Chen, Full-Young Chang, Han-Chieh Lin, Shou-Dong Lee.   

Abstract

BACKGROUND/AIMS: Drug metabolizing enzymes may be related to drug-induced liver injury (DILI). Manganese superoxide dismutase (MnSOD), NAD(P)H:quinone oxidoreductase (NQO1), and glutathione S-transferase (GST) are important drug metabolizing enzymes. We aimed to elucidate the relationship between genetic polymorphisms of these enzymes and the susceptibility to DILI.
METHODS: A total of 115 patients with DILI and 115 drug-, sex-, and age-matched controls were enrolled. Their genetic polymorphisms of MnSOD, NQO1, GSTM1, and GSTT1 were assayed.
RESULTS: Sixty-three (54.8%) of DILI patients were incriminated to anti-tuberculosis drugs. Subjects with a mutant C allele (T/C or C/C genotype) of MnSOD had a higher risk of DILI than those with MnSOD T/T genotype, both in overall drugs studied (adjusted OR: 2.44, 95% C.I.: 1.38-4.30, P=0.002), and in sub-category of anti-tuberculosis drugs (adjusted OR: 2.47, 95% C.I.: 1.13-5.39, P=0.02). In addition, subjects carrying GSTM1 null genotype had increased risk of anti-tuberculosis DILI (adjusted OR: 2.23, 95% C.I.: 1.07-4.67, P=0.03).
CONCLUSIONS: The MnSOD mutant C allele may increase the susceptibility to DILI, and GSTM1 null genotype may be related to anti-tuberculosis drug-induced hepatotoxicity. Determination of the MnSOD and GSTM1 genotypes may help identify patients at high risk for DILI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400324     DOI: 10.1016/j.jhep.2007.02.009

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  52 in total

1.  PharmGKB summary: very important pharmacogene information for GSTT1.

Authors:  Caroline F Thorn; Yuan Ji; Richard M Weinshilboum; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-08       Impact factor: 2.089

2.  NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.

Authors:  Rika Yuliwulandari; Retno Wilujeng Susilowati; Britanto Dani Wicaksono; Kencono Viyati; Kinasih Prayuni; Intan Razari; Erna Kristin; Eva Sri Diana; Suci Setiawati; Aziza Ariyani; Surakameth Mahasirimongkol; Hideki Yanai; Taisei Mushiroda; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

Review 3.  Pharmacogenomics of antimicrobial agents.

Authors:  Ar Kar Aung; David W Haas; Todd Hulgan; Elizabeth J Phillips
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

4.  A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease.

Authors:  Luca Miele; Valentina Dall'armi; Consuelo Cefalo; Bojan Nedovic; Dario Arzani; Rosarita Amore; Gianlodovico Rapaccini; Antonio Gasbarrini; Walter Ricciardi; Antonio Grieco; Stefania Boccia
Journal:  Genes Nutr       Date:  2014-01-09       Impact factor: 5.523

Review 5.  Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.

Authors:  Vidyasagar Ramappa; Guruprasad P Aithal
Journal:  J Clin Exp Hepatol       Date:  2012-12-20

Review 6.  Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.

Authors:  Volker M Lauschke; Lili Milani; Magnus Ingelman-Sundberg
Journal:  AAPS J       Date:  2017-11-27       Impact factor: 4.009

Review 7.  Risk factors for idiosyncratic drug-induced liver injury.

Authors:  Naga Chalasani; Einar Björnsson
Journal:  Gastroenterology       Date:  2010-04-12       Impact factor: 22.682

Review 8.  Practical guidelines for diagnosis and early management of drug-induced liver injury.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

Review 9.  GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis.

Authors:  C Li; J Long; X Hu; Y Zhou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-02       Impact factor: 3.267

Review 10.  Current concepts of mechanisms in drug-induced hepatotoxicity.

Authors:  Stefan Russmann; Gerd A Kullak-Ublick; Ignazio Grattagliano
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.